MORGAN HANKINS: Open Payments
NPI 1750038758 · RIDGEWAY, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,915 in 185 payments from 29 companies in 2025. Trend: 2023 $1,651 · 2024 $2,834 · 2025 $2,915
Food & beverage: $2,915
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $408 |
| Otsuka America Pharmaceutical, Inc. | 17 | $264 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $231 |
| Lilly USA, LLC | 19 | $228 |
| Lundbeck LLC | 18 | $218 |
| AstraZeneca Pharmaceuticals LP | 8 | $192 |
| Novo Nordisk Inc | 9 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $123 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $115 |
| Janssen Pharmaceuticals, Inc | 6 | $113 |
Products named: REXULTI, CAPLYTA, FARXIGA, VRAYLAR, MOUNJARO, TRINTELLIX, XIFAXAN, SPRAVATO.
Industry payments across VA — which companies pay providers there.
